Results we already knew about for cabozantinib in mCRPC

Back in September 2014, Exelixis had announced (and we had reported) the failure of the COMET-1 trial to show a meaningful survival benefit for treatment with cabozantinib in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Personalized medicine is coming to life in management of advanced prostate cancer

A new study reported today in the New England Journal of Medicine is suggesting that every man with metastatic prostate cancer (regardless of his age or family history) should be tested for certain particular inherited mutations. … READ MORE …

Abiraterone + veliparib in treatment of men with mCRPC

Another important set of data that came out of the ASCO session that your sitemaster was unable to attend were the data presented by Dr. Maha Hussain on the use of the PARP inhibitor veliparib.

Ipataserib + abiraterone in the treatment of post-chemo mCRPC

One of the more provocative papers to be presented this year at the annual meeting of  the American Society of Clinical Oncology is by De Bono et al. from a large, randomized Phase II trial of a drug called GDC-0068 or ipataserib. … READ MORE …

Current management of men with nmCRPC: a review

A new review article in the journal Oncology provides an excellent and relatively brief overview of the current options and recommendations for treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Clinical effects of abiraterone acetate in the “real world”

It is well understood that drugs can demonstrate better results during the highly controlled, closely monitored setting of a clinical trial than they do in the “real world”. … READ MORE …

Everolimus + bicalutamide in treatment of CRPC?

A small, single-institution, Phase II clinical trial has suggested the possibility that everolimus + bicalutamide may have useful activity in the treatment of some men with castration-resistant prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,451 other followers